Allarity Therapeutics, Inc. (ALLR) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 5, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the ALLR SEC filings page.
Allarity Therapeutics, Inc. (ALLR) reported $320K in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
The numbers describe a development-stage business whose small early revenue is still outweighed by research spending and recurring cash needs.
In FY2025, revenue was$320K while research and development spending reached$6.6M , so the reported business remains organized around development rather than sales. With selling, general and administrative costs at$6.3M and operating cash flow of-$14.8M , that cost structure is visible in cash as well as accounting losses.
Operating cash flow improved from
Free cash flow of
Financial Health Signals
Allarity Therapeutics, Inc. does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Allarity Therapeutics, Inc. scores -10.49, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($15.9M) relative to total liabilities ($8.4M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Allarity Therapeutics, Inc. passes 4 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, both operating efficiency signals pass.
Allarity Therapeutics, Inc. reported a net loss of $11.2M while operations used $14.8M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Allarity Therapeutics, Inc. reported an operating loss of $12.6M against $185K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.
Key Financial Metrics
Earnings & Revenue
Allarity Therapeutics, Inc. generated $0 in revenue in Q2 2026. Against the prior quarter it is down 100.0%.
Allarity Therapeutics, Inc. reported -$3.4M in net income in Q2 2026. This represents a decrease of 46.8% from the same quarter a year earlier. Against the prior quarter it is down 23.8%.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Allarity Therapeutics, Inc. recorded an outflow of $2.6M in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 53.2% from the same quarter a year earlier. Against the prior quarter it is up 43.7%.
Allarity Therapeutics, Inc. held $17.0M in cash as of Q2 2026; long-term debt is not reported for that period.
Not reported for Q2 2026.
Margins & Returns
Allarity Therapeutics, Inc.'s ROE was -96.3% in Q2 2026, measuring profit generated per dollar of shareholder equity. This is down 77.2 percentage points from the same quarter a year earlier. Against the prior quarter it is down 56.6 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Allarity Therapeutics, Inc. invested $1.3M in research and development in Q2 2026. This represents a decrease of 42.1% from the same quarter a year earlier. Against the prior quarter it is up 3.7%.
Allarity Therapeutics, Inc. repurchased no shares in Q2 2026. This represents a decrease of 100.0% from the same quarter a year earlier. Against the prior quarter it is down 100.0%.
Allarity Therapeutics, Inc. reported no capital expenditure in Q2 2026. Against the prior quarter it is down 100.0%.
ALLR Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $25K | N/A | N/A | $0 | $0 | N/A | N/A |
| R&D Expenses | $1.3M-42.1% | $1.3M-7.6% | N/A | $1.2M+17.8% | $2.3M+119.4% | $1.4M-35.3% | N/A | $1.0M-47.6% |
| SG&A Expenses | $1.3M-26.8% | $1.4M-13.3% | N/A | $1.3M-17.2% | $1.8M-21.7% | $1.6M-21.1% | N/A | $1.6M-35.9% |
| Operating Income | -$2.7M+35.4% | -$2.7M+11.5% | N/A | -$2.5M+79.6% | -$4.1M-22.6% | -$3.0M+28.4% | N/A | -$12.3M-178.2% |
| EBITDA | N/A | N/A | N/A | N/A | -$4.1M-22.3% | -$3.0M+28.6% | N/A | N/A |
| Interest Expense | $719K+5891.7% | $229K+301.8% | N/A | $57K+14.0% | $12K-97.2% | $57K-44.1% | N/A | $50K+47.1% |
| Income Tax | N/A | N/A | N/A | $0+100.0% | $0 | $0+100.0% | N/A | -$377K |
| Net Income | -$3.4M-46.8% | -$2.8M-0.7% | N/A | -$2.8M+75.8% | -$2.3M-42.4% | -$2.7M+28.9% | N/A | -$11.6M-160.6% |
| EPS (Basic) | -$0.21-40.0% | -$0.17+32.0% | -$0.21-102.2% | -$0.19+97.5% | -$0.15+95.5% | -$0.25+62.4% | $9.68+6.1% | -$7.71-472.8% |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, EPS (Diluted), Diluted Shares (Avg).
ALLR Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $32.1M+51.5% | $34.9M+17.5% | $18.3M-19.4% | $20.8M+2.1% | $21.2M-31.3% | $29.7M+148.4% | $22.6M+90.9% | $20.4M+46.9% |
| Current Assets | $31.7M+51.9% | $34.5M+17.3% | $17.9M-19.8% | $20.5M+0.5% | $20.9M-2.0% | $29.4M+1182.0% | $22.3M+1033.5% | $20.4M+364.2% |
| Cash & Equivalents | $17.0M-4.6% | $19.8M-21.4% | $14.7M-24.8% | $16.9M-8.7% | $17.8M-7.4% | $25.2M+7977.2% | $19.5M+11666.9% | $18.5M+1222.4% |
| Short-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $28.6M+216.2% | $28.0M+153.2% | $8.4M-22.2% | $8.8M+18.5% | $9.0M-18.2% | $11.1M-40.0% | $10.8M-25.8% | $7.4M-57.0% |
| Current Liabilities | $28.6M+216.2% | $28.0M+153.2% | $8.4M-22.2% | $8.8M+18.5% | $9.0M-14.9% | $11.1M-38.6% | $10.8M-23.5% | $7.4M-52.9% |
| Non-Current Liabilities | $0 | $0 | $0 | $0 | $0-100.0% | $0-100.0% | $0-100.0% | $0-100.0% |
| Total Equity | $3.5M-70.9% | $6.9M-62.9% | $9.8M-16.8% | $12.0M-7.4% | $12.2M-38.7% | $18.7M+388.5% | $11.8M+529.3% | $13.0M+483.7% |
| Retained Earnings | -$136.4M-9.9% | -$132.9M-9.2% | -$130.2M-9.4% | -$126.8M-13.7% | -$124.0M-24.1% | -$121.7M-23.8% | -$119.0M-26.0% | -$111.5M-20.3% |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
ALLR Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.6M+53.2% | -$4.5M-67.3% | -$3.2M-1.2% | -$3.4M+37.4% | -$5.5M+25.0% | -$2.7M-92.0% | -$3.2M-91.7% | -$5.4M-1.2% |
| Depreciation & Amortization | N/A | N/A | N/A | N/A | $12K+1100.0% | $11K+450.0% | N/A | N/A |
| Stock-Based Compensation | $188K+14.6% | $160K+15.1% | N/A | $132K+676.5% | $164K+645.5% | $139K+534.4% | N/A | $17K-90.6% |
| Capital Expenditures | $0 | $64K | N/A | N/A | $0 | $0 | N/A | N/A |
| Free Cash Flow | -$2.6M+53.2% | -$4.6M-69.7% | N/A | N/A | -$5.5M | -$2.7M | N/A | N/A |
| Investing Cash Flow | $0 | -$64K | N/A | N/A | $0 | $0 | N/A | N/A |
| Financing Cash Flow | $0+100.0% | $19.7M+77.2% | -$240K-105.7% | $2.3M-52.5% | -$2.6M-109.7% | $11.1M+707.5% | $4.2M+711.3% | $4.9M-24.5% |
| Share Buybacks | $0-100.0% | $262K | $484K | $141K | $2.6M | $0 | $0 | $0 |
Not reported in any period shown, so not listed: Dividends Paid.
ALLR Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Margin | N/A | -10752.0% | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | -11000.0% | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -96.3%-77.2pp | -39.7%-25.1pp | N/A | -23.4%+66.0pp | -19.1%-10.9pp | -14.6% | N/A | -89.4% |
| Return on Assets | -10.6%+0.3pp | -7.9%+1.3pp | N/A | -13.5%+43.4pp | -10.9%-5.7pp | -9.2%+22.9pp | N/A | -56.9%-24.8pp |
| Current Ratio | 1.11-1.2x | 1.23-1.4x | 2.13+0.1x | 2.33-0.4x | 2.31+0.3x | 2.66+2.5x | 2.06+1.9x | 2.75+2.5x |
| Debt-to-Equity | 8.08+7.3x | 4.05+3.5x | 0.86-0.1x | 0.73+0.2x | 0.74+0.2x | 0.59 | 0.92 | 0.57 |
| Asset Turnover | 0.000.0x | 0.000.0x | N/A | N/A | 0.00 | 0.00 | N/A | N/A |
| FCF Margin | N/A | -18228.0% | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Allarity Therapeutics, Inc. ALLR | FY2025 | $320K | -$11.2M | N/A | $15.9M | — |
| Boundless Bio, Inc. BOLD | FY2025 | N/A | -$58.2M | N/A | $59.6M | — |
| Kezar Life Sciences, Inc. KZR | FY2025 | $0 | -$56.0M | N/A | $53.9M | — |
| Tenax Therapeutics, Inc. TENX | FY2025 | $0 | -$52.6M | N/A | $74.1M | — |
| Neuphoria Therapeutics Inc. NEUP | FY2026 | $1.2M | -$13.5M | N/A | $18.8M | 48/100 |
| Akari Therapeutics plc AKTX | FY2025 | N/A | -$17.3M | N/A | $19.9M | — |
Where Allarity Therapeutics, Inc. Ranks
Frequently Asked Questions
What is Allarity Therapeutics, Inc.'s annual revenue?
Allarity Therapeutics, Inc. (ALLR) reported $320K in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Allarity Therapeutics, Inc. profitable?
No, Allarity Therapeutics, Inc. (ALLR) reported a net income of -$11.2M in fiscal year 2025.
What is Allarity Therapeutics, Inc.'s return on equity (ROE)?
Allarity Therapeutics, Inc. (ALLR) has a return on equity of -114.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Allarity Therapeutics, Inc.'s free cash flow?
Allarity Therapeutics, Inc. (ALLR) recorded an outflow of $14.8M in free cash flow during fiscal year 2025. This represents a 16.0% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Allarity Therapeutics, Inc.'s operating cash flow?
Allarity Therapeutics, Inc. (ALLR) recorded an outflow of $14.8M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Allarity Therapeutics, Inc.'s total assets?
Allarity Therapeutics, Inc. (ALLR) had $18.3M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Allarity Therapeutics, Inc.'s capital expenditures?
Allarity Therapeutics, Inc. (ALLR) invested $8K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Allarity Therapeutics, Inc. spend on research and development?
Allarity Therapeutics, Inc. (ALLR) invested $6.6M in research and development during fiscal year 2025.
What is Allarity Therapeutics, Inc.'s current ratio?
Allarity Therapeutics, Inc. (ALLR) had a current ratio of 2.13 as of fiscal year 2025, which is generally considered healthy.
What is Allarity Therapeutics, Inc.'s debt-to-equity ratio?
Allarity Therapeutics, Inc. (ALLR) had a debt-to-equity ratio of 0.86 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Allarity Therapeutics, Inc.'s return on assets (ROA)?
Allarity Therapeutics, Inc. (ALLR) had a return on assets of -61.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Allarity Therapeutics, Inc.'s P/E ratio?
Allarity Therapeutics, Inc. (ALLR) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $15.9M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Allarity Therapeutics, Inc.'s price-to-sales ratio?
Allarity Therapeutics, Inc. (ALLR) trades at 49.7x sales, its market capitalization divided by revenue of $320K revenue, FY2025. The market capitalization is $15.9M as of Oct 5, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
How does Allarity Therapeutics, Inc.'s liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Allarity Therapeutics, Inc. (ALLR) held $14.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $14.8M over that year. Dividing the one by the other, the reported balance equals about 12 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Allarity Therapeutics, Inc.'s Altman Z-Score?
Allarity Therapeutics, Inc. (ALLR) has an Altman Z-Score of -10.49, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Allarity Therapeutics, Inc.'s Piotroski F-Score?
Allarity Therapeutics, Inc. (ALLR) has a Piotroski F-Score of 4 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Allarity Therapeutics, Inc.'s earnings high quality?
Allarity Therapeutics, Inc. (ALLR) reported a net loss of $11.2M while operations used $14.8M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can Allarity Therapeutics, Inc. cover its interest payments?
Allarity Therapeutics, Inc. (ALLR) reported an operating loss of $12.6M against $185K in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.